Items where Author is "Mohr, A"

Article

Leach, DA and Mohr, A and Giotis, ES and Cil, E and Isac, AM and Yates, LL and Barclay, WS and Zwacka, RM and Bevan, CL and Brooke, GN (2021) The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells. Nature Communications, 12 (1). 4068-. DOI https://doi.org/10.1038/s41467-021-24342-y

Mohr, A and Zwacka, RM (2018) The future of mesenchymal stem cell-based therapeutic approaches for cancer – From cells to ghosts. Cancer Letters, 414. pp. 239-249. DOI https://doi.org/10.1016/j.canlet.2017.11.025

Yu, R and Deedigan, L and Albarenque, SM and Mohr, A and Zwacka, RM (2013) Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects. Cell Death & Disease, 4 (2). e503-e503. DOI https://doi.org/10.1038/cddis.2013.19

Mohr, A and Büneker, C and Gough, RP and Zwacka, RM (2008) MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release. Oncogene, 27 (6). pp. 763-774. DOI https://doi.org/10.1038/sj.onc.1210673

Mohr, A and Lyons, M and Mohr, W and Zwacka, RM (2007) Gentherapeutische Strategien gegen das kolorektale Karzinom [Gene therapy strategies for colorectal cancer]. Deutsche medizinische Wochenschrift (1946), 132 (11). pp. 567-570.

Mohr, A and Henderson, G and Dudus, L and Herr, I and Kuerschner, T and Debatin, K-M and Weiher, H and Fisher, KJ and Zwacka, RM (2004) AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression. Gene Therapy, 11 (6). pp. 534-543. DOI https://doi.org/10.1038/sj.gt.3302154